Literature DB >> 70709

HLA antigens in Guillain-Barré syndrome.

D Adams, J D Gibson, P K Thomas, J R Batchelor, R A Hughes, L Kennedy, H Festenstein, J Sachs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 70709      PMCID： PMC8334663          DOI： 10.1016/s0140-6736(77)91626-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  HLA antigens in chronic inflammatory demyelinating polyneuropathy.

Authors:  D J Feeney; J D Pollard; J G McLeod; G J Stewart; T J Doran
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

2.  Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Authors:  L Schirmer; V Worthington; U Solloch; V Loleit; V Grummel; N Lakdawala; D Grant; R Wassmuth; A H Schmidt; F Gebhardt; T F M Andlauer; J Sauter; A Berthele; M P Lunn; Bernhard Hemmer
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

3.  HLA antigens in chronic relapsing idiopathic inflammatory polyneuropathy.

Authors:  D Adams; H Festenstein; J D Gibson; R A Hughes; J Jaraquemada; C Papasteriadis; J Sachs; P K Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

4.  The treatment of inflammatory polyneuropathy by plasma exchange.

Authors:  M L Gross; N J Legg; M C Lockwood; C Pallis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-08       Impact factor: 10.154

Review 5.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 6.  Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Authors:  Esmée P Hoefsmit; Elisa A Rozeman; John B A G Haanen; Christian U Blank
Journal:  ESMO Open       Date:  2019-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.